These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24127451)

  • 1. Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa.
    Ades F
    J Clin Oncol; 2013 Nov; 31(33):4271. PubMed ID: 24127451
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to F. Ades.
    Guan Z
    J Clin Oncol; 2013 Nov; 31(33):4272. PubMed ID: 24127453
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies: HER2-positive breast cancer-sifting through many good options.
    Krop IE
    Nat Rev Clin Oncol; 2013 Jun; 10(6):312-3. PubMed ID: 23629473
    [No Abstract]   [Full Text] [Related]  

  • 5. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Of mice and (wo)men: is this any way to test a new drug?
    Haddad TC; Yee D
    J Clin Oncol; 2008 Feb; 26(6):830-2. PubMed ID: 18281652
    [No Abstract]   [Full Text] [Related]  

  • 8. A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
    Jagiello-Gruszfeld A; Tjulandin S; Dobrovolskaya N; Manikhas A; Pienkowski T; DeSilvio M; Ridderheim M; Abbey R
    Oncology; 2010; 79(1-2):129-35. PubMed ID: 21088439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
    Abramovitz M; Williams C; Loibl S; Leyland-Jones B
    Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.
    Castañeda CA; Gomez HL
    Nat Rev Clin Oncol; 2009 Jun; 6(6):308-9. PubMed ID: 19483734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin?
    Loibl S
    JAMA Oncol; 2015 Jul; 1(4):455-6. PubMed ID: 26181253
    [No Abstract]   [Full Text] [Related]  

  • 14. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
    Kroep JR; Linn SC; Boven E; Bloemendal HJ; Baas J; Mandjes IA; van den Bosch J; Smit WM; de Graaf H; Schröder CP; Vermeulen GJ; Hop WC; Nortier JW
    Neth J Med; 2010 Sep; 68(9):371-6. PubMed ID: 20876920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib in second-line treatment for metastatic breast cancer: rapid clinical benefit and long-term response.
    De Tursi M; Carella C
    Tumori; 2013; 99(6):261e-3e. PubMed ID: 24503799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New treatment approaches in breast cancer].
    Spirig C; Thürlimann B; Huober J
    Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.